Keyphrases
Nonalcoholic Steatohepatitis
100%
Vitamin E
100%
Haptoglobin
100%
Histological Response
100%
Placebo
40%
Liver Enzymes
40%
Haptoglobin Genotype
40%
Steatohepatitis
20%
Regression Analysis
20%
Histologic Improvement
20%
Clinical Trials
10%
Oxidative Stress
10%
Histology
10%
Alanine Aminotransferase
10%
Histopathological Features
10%
Alkaline Phosphatase
10%
Regression Model
10%
Enhanced Resolution
10%
Fibrosis Stage
10%
Non-alcoholic Fatty Liver Disease (NAFLD)
10%
End of Treatment
10%
Cardiovascular Outcomes
10%
Genotype 1
10%
Aspartate Aminotransferase
10%
Patients with Diabetes Mellitus
10%
Laboratory Markers
10%
Interaction Terms
10%
Stress Outcomes
10%
Glutamyl Transpeptidase
10%
Differential Treatment Effects
10%
Incremental Benefits
10%
Treatment Value
10%
Nonalcoholic Fatty Liver Disease Activity Score
10%
Biological Improvement
10%
Medicine and Dentistry
Nonalcoholic Fatty Liver
100%
Allele
100%
Alpha Tocopherol
100%
Haptoglobin
100%
Placebo
36%
Liver Enzyme
36%
Steatohepatitis
18%
Clinical Trial
9%
Cardiovascular System
9%
Alanine Aminotransferase
9%
Aspartate Aminotransferase
9%
Oxidative Stress
9%
Diabetes Mellitus
9%
Fibrosis
9%
Patient with Diabetes
9%
Treatment Effect
9%
Gamma-Glutamyl Transpeptidase
9%
Post-Hoc Analysis
9%
Alkaline Phosphatase
9%
Nonalcoholic Fatty Liver Disease Activity Score
9%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
100%
Alpha Tocopherol
100%
Haptoglobin
100%
Placebo
36%
Liver Enzyme
36%
Fibrosis
9%
Clinical Trial
9%
Aspartate Aminotransferase
9%
Alanine Aminotransferase
9%
Diabetes Mellitus
9%
Gamma Glutamyltransferase
9%
Alkaline Phosphatase
9%
Disease Activity Score
9%